<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pain Res</journal-id><journal-id journal-id-type="iso-abbrev">J Pain Res</journal-id><journal-id journal-id-type="publisher-id">Journal of Pain Research</journal-id><journal-title-group><journal-title>Journal of Pain Research</journal-title></journal-title-group><issn pub-type="epub">1178-7090</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25120375</article-id><article-id pub-id-type="pmc">4128837</article-id><article-id pub-id-type="doi">10.2147/JPR.S66741</article-id><article-id pub-id-type="publisher-id">jpr-7-449</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Transdermal fentanyl patch for postoperative analgesia in total knee arthroplasty: a randomized double-blind controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sathitkarnmanee</surname><given-names>Thepakorn</given-names></name><xref ref-type="aff" rid="af1-jpr-7-449">1</xref><xref ref-type="corresp" rid="c1-jpr-7-449"/></contrib><contrib contrib-type="author"><name><surname>Tribuddharat</surname><given-names>Sirirat</given-names></name><xref ref-type="aff" rid="af1-jpr-7-449">1</xref></contrib><contrib contrib-type="author"><name><surname>Noiphitak</surname><given-names>Kanlayarat</given-names></name><xref ref-type="aff" rid="af2-jpr-7-449">2</xref></contrib><contrib contrib-type="author"><name><surname>Theerapongpakdee</surname><given-names>Sunchai</given-names></name><xref ref-type="aff" rid="af1-jpr-7-449">1</xref></contrib><contrib contrib-type="author"><name><surname>Pongjanyakul</surname><given-names>Sasiwimon</given-names></name><xref ref-type="aff" rid="af1-jpr-7-449">1</xref></contrib><contrib contrib-type="author"><name><surname>Huntula</surname><given-names>Yuwadee</given-names></name><xref ref-type="aff" rid="af1-jpr-7-449">1</xref></contrib><contrib contrib-type="author"><name><surname>Thananun</surname><given-names>Maneerat</given-names></name><xref ref-type="aff" rid="af1-jpr-7-449">1</xref></contrib></contrib-group><aff id="af1-jpr-7-449"><label>1</label>Department of Anesthesiology, Faculty of Medicine, Khon Kaen University, Khon Kaen</aff><aff id="af2-jpr-7-449"><label>2</label>Chulabhorn Hospital, Bangkok, Thailand</aff><author-notes><corresp id="c1-jpr-7-449">Correspondence: Thepakorn Sathitkarnmanee, Department of Anesthesiology, Faculty of Medicine, Khon Kaen University, 123 Moo 16 Mittraphap Road, Tambon Muang, Khon Kaen 40002, Thailand, Tel +66 81 954 7622, Fax +66 43 348 390, Email <email>thepakorns@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>01</day><month>8</month><year>2014</year></pub-date><volume>7</volume><fpage>449</fpage><lpage>454</lpage><permissions><copyright-statement>&#x000a9; 2014 Sathitkarnmanee et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2014</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To assess the efficacy of a transdermal fentanyl patch (TFP) (50 &#x003bc;g/hour) applied 10&#x02013;12 hours before surgery versus placebo for postoperative pain control of total knee arthroplasty (TKA).</p></sec><sec><title>Materials and methods</title><p>We enrolled 40 patients undergoing elective TKA under spinal anesthesia using isobaric or hyperbaric bupivacaine. Subjects were randomized to receive a TFP (Duragesic<sup>&#x000ae;</sup> 50 &#x003bc;g/hour) or placebo patch applied with a self-adhesive to the anterior chest wall 10&#x02013;12 hours before spinal anesthesia. Every patient was given patient-controlled morphine for postoperative pain control. Patients were evaluated every 4 hours until 48 hours.</p></sec><sec><title>Results</title><p>Morphine consumption at 24 and 48 hours in the TFP group versus the placebo group was 15.40&#x000b1;12.65 and 24.90&#x000b1;20.11 mg versus 33.60&#x000b1;19.06 and 57.80&#x000b1;12.65 mg (<italic>P</italic>&#x02264;0.001). Numeric rating scale scores at rest and during movement over 48 hours were lower in the TFP group. Ambulation and nausea/vomiting scores were statistically greater, but not clinically significant in the TFP group. Sedation scores were low and not statistically significantly different between groups. There was no severe respiratory depression.</p></sec><sec><title>Conclusion</title><p>TFP (50 &#x003bc;g/hour) applied 10&#x02013;12 hours before surgery can effectively and safely decrease morphine consumption and pain scores during the first 48 hours after TKA surgery.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>analgesia</kwd><kwd>total knee arthroplasty</kwd><kwd>fentanyl</kwd><kwd>matrix transdermal delivery system</kwd><kwd>patient-controlled analgesia</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Total knee arthroplasty (TKA) is a surgery that improves patient mobility and quality of life, but causes severe postoperative pain during the first 24&#x02013;72 hours.<xref rid="b1-jpr-7-449" ref-type="bibr">1</xref> Adequate postoperative pain control promotes patient ambulation and physiotherapy,<xref rid="b2-jpr-7-449" ref-type="bibr">2</xref> leading to early recovery, fewer complications (ie, deep-vein thrombosis or nosocomial infection), and a shorter hospital stay.<xref rid="b3-jpr-7-449" ref-type="bibr">3</xref> There are many methods for relieving postoperative pain in TKA, including patient-controlled analgesia (PCA),<xref rid="b4-jpr-7-449" ref-type="bibr">4</xref> patient-controlled epidural analgesia,<xref rid="b4-jpr-7-449" ref-type="bibr">4</xref> spinal morphine,<xref rid="b5-jpr-7-449" ref-type="bibr">5</xref> femoral nerve block,<xref rid="b3-jpr-7-449" ref-type="bibr">3</xref> and continuous posterior lumbar plexus block.<xref rid="b6-jpr-7-449" ref-type="bibr">6</xref> These methods, however, require personal skills and expensive equipment.</p><p>The transdermal fentanyl patch (TFP) is a skin-patch opioid that steadily releases fentanyl into the bloodstream according to the dosage applied.<xref rid="b7-jpr-7-449" ref-type="bibr">7</xref> The subsequent plasma level and clearance are similar to intravenous use.<xref rid="b8-jpr-7-449" ref-type="bibr">8</xref> TFPs are commonly used for chronic pain management.<xref rid="b9-jpr-7-449" ref-type="bibr">9</xref>,<xref rid="b10-jpr-7-449" ref-type="bibr">10</xref> Typically, a TFP has a slow onset (plateauing in 15 hours), which makes it inappropriate for acute pain control.<xref rid="b11-jpr-7-449" ref-type="bibr">11</xref>&#x02013;<xref rid="b13-jpr-7-449" ref-type="bibr">13</xref> If, however, it is applied 12&#x02013;14 hours before surgery, it may effectively relieve postoperative pain in TKA.</p><p>Our hypothesis was that a TFP (50 &#x003bc;g/hour) applied 10&#x02013;12 hours before surgery would provide superior analgesia for 48 hours compared with placebo for postoperative pain control in TKA. The primary outcome was a difference in cumulative morphine consumption at 48 hours after surgery.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>The current study was approved by the Institutional Review Board of Khon Kaen University (HE521183) and registered at <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (NCT01348984). Written informed consent was obtained from all subjects.</p><p>Our study was a prospective randomized double-blind controlled trial. Using Minville et al<xref rid="b14-jpr-7-449" ref-type="bibr">14</xref> as a guide, we determined that for an <italic>&#x003b1;</italic>-value of 0.05 and a power (1-&#x003b2;) of 0.80, the sample size needed to be 19 patients in each group. We recruited 40 patients to cover dropout. Randomization was achieved using a computer-generated list kept in sealed opaque envelopes. We included patients between 20 and 80 years of age, scheduled for elective TKA under spinal anesthesia, having an American Society of Anesthesiologists (ASA) physical status of I&#x02013;II, and able to use a PCA. We excluded patients who: 1) were pregnant or breastfeeding, 2) had a history of allergy to TFPs or morphine, 3) had a contraindication for spinal anesthesia, 4) had major organ diseases, and 5) had a history of drug abuse.</p><p>The patients, admitted 1 day prior to the surgery, were then allocated to two groups: group T received a single TFP (Duragesic<sup>&#x000ae;</sup> 50 &#x003bc;g/hour matrix fentanyl patch; Janssen Pharmaceutica, Beerse, Belgium) affixed to the anterior chest wall 10&#x02013;12 hours before surgery by the preoperative-visit resident; and group P received a placebo patch in the same manner. Spinal anesthesia was given using either hyperbaric or isobaric bupivacaine at a standard dosage. All of the patients received standard intraoperative monitoring and care. After surgery, they were transferred to the postanesthetic care unit. Time of arrival at the unit represented time 0. The severity of pain was determined using a numeric rating scale (NRS). PCA was started after the NRS had fallen to &#x02264;3 in response to intravenous morphine supplementation (at 2 mg/5 minute intervals). The PCA device was set at 1 mg of morphine with a 5-minute lockout and a 1-hour limit of 8 mg. Every 4 hours until 48 hours, we recorded morphine consumption, blood pressure, respiratory rate, NRS score at rest and when moving, ambulation, sedation, and nausea/vomiting (N/V) score. The TFP was removed at 48 hours (<xref ref-type="fig" rid="f1-jpr-7-449">Figure 1</xref>).</p><p>Ambulation scoring was 0= unable to sit up in bed, 1= able to sit up in bed, 2= able to sit on the edge of the bed with feet hanging down over the side, and 3= able to move from bed to a chair with assistance. Sedation scoring was 0= fully alert, 1= mild sedation, easy to rouse, 2= moderate sedation, arousable with gentle shaking, and 3= deep sedation, not aroused by speaking or gentle shaking. N/V scores were 0= none, 1= mild, 2= moderate, and 3= severe. We noted all adverse effects and postoperative complications, such as itching and severe respiratory depression (respiration rate &#x02264;8 breaths/minute).</p><p>Statistical analyses were performed using SPSS 17.0 for Windows (SPSS, Chicago, IL, USA). Continuous data are presented as mean (standard deviation) and categorical data as n (%). To compare the differences between groups, Student&#x02019;s <italic>t</italic>-test, <italic>&#x003c7;</italic><sup>2</sup> test, or analysis of variance was used as applicable. <italic>P</italic>&#x0003c;0.05 was considered statistically significant.</p></sec><sec sec-type="results"><title>Results</title><p>A total of 40 patients completed the study. The demographic data and anesthetic time for both groups were comparable (<xref ref-type="table" rid="t1-jpr-7-449">Table 1</xref>). Compared to the placebo, the TFP significantly reduced cumulative morphine consumption over 24 and 48 hours by 54.2% and 56.9%, respectively (ie, 18.2 and 32.9 mg; <xref ref-type="table" rid="t2-jpr-7-449">Table 2</xref> and <xref ref-type="fig" rid="f2-jpr-7-449">Figure 2</xref>). The average NRS scores at rest and during joint movement over the 48 hours were significantly lower in group T (<xref ref-type="fig" rid="f3-jpr-7-449">Figure 3</xref>). In addition, ambulation scores over 48 hours were significantly higher in group T. Sedation scores over 48 hours were not significantly different between the groups. N/V scores over 48 hours were significantly higher in group T (<xref ref-type="table" rid="t2-jpr-7-449">Table 2</xref>). There was no severe respiratory depression.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Our study demonstrates that a TFP (50 &#x003bc;g/hour) applied 10&#x02013;12 hours before surgery can safely relieve postoperative pain from TKA for 48 hours. Over 24 and 48 hours, the TFP reduced morphine consumption by 54.2% and 56.9%, respectively. Importantly, NRS scores were lower both at rest and during movement, with comparable low sedation scores. Although ambulation and N/V scores were statistically different, there was no clinical significance, as both scores were lower than 1.</p><p>The results of the present study are in accord with previous studies in which TFPs provided dose-dependent analgesia after lower abdominal surgery.<xref rid="b15-jpr-7-449" ref-type="bibr">15</xref> A TFP administering 75 &#x003bc;g/hour is also used as a safe and effective analgesic after major shoulder surgery.<xref rid="b16-jpr-7-449" ref-type="bibr">16</xref> Other studies showed that TFPs can safely reduce morphine consumption and pain scores for patients undergoing hemorrhoidectomy,<xref rid="b17-jpr-7-449" ref-type="bibr">17</xref> major urological operations,<xref rid="b18-jpr-7-449" ref-type="bibr">18</xref> abdominal surgery,<xref rid="b19-jpr-7-449" ref-type="bibr">19</xref> and total hip arthroplasty.<xref rid="b14-jpr-7-449" ref-type="bibr">14</xref> By contrast, some studies have reported that TFPs did not significantly relieve postoperative pain.<xref rid="b20-jpr-7-449" ref-type="bibr">20</xref>,<xref rid="b21-jpr-7-449" ref-type="bibr">21</xref> In the latter, the TFP was placed just before or within 2 hours of surgery. For TFPs to be effective, its serum level must plateau (ie, 15 hours after being affixed), which would be before the end of surgery.<xref rid="b13-jpr-7-449" ref-type="bibr">13</xref> Osipova et al studied the effect of TFPs for prevention and treatment of postoperative pain syndrome in extensive thoracoabdominal oncological surgery, and concluded that TFPs in the early postoperative period may prevent acute opioid tolerance and hyperalgesia, underscoring the benefit of their use in multimodal postoperative analgesia with nonsteroidal anti-inflammatory drugs (NSAIDs).<xref rid="b22-jpr-7-449" ref-type="bibr">22</xref></p><p>Although we did not encounter any severe respiratory depression, this may have been due to the small sample size, as in other studies.<xref rid="b14-jpr-7-449" ref-type="bibr">14</xref>&#x02013;<xref rid="b19-jpr-7-449" ref-type="bibr">19</xref> The adverse effects of TFPs are dose-dependent, as with other narcotic administration. Sedation scores do not increase, albeit reductions in the respiratory rate rise, with doses up to 75 &#x003bc;g/hour.<xref rid="b15-jpr-7-449" ref-type="bibr">15</xref>,<xref rid="b16-jpr-7-449" ref-type="bibr">16</xref>,<xref rid="b23-jpr-7-449" ref-type="bibr">23</xref> We concur with Bulow et al that a TFP administering 100 &#x003bc;g/hour would be too potent, because of the potential for life-threatening respiratory depression.<xref rid="b24-jpr-7-449" ref-type="bibr">24</xref> For patient safety, we chose the lower dosage, ie, 50 &#x003bc;g/hour, for our study. Nevertheless, Cole et al reported that variability of TFP metabolism and excretion in pain patients contributed to unpredictable adverse effects.<xref rid="b25-jpr-7-449" ref-type="bibr">25</xref> In a review, Nelson and Schwaner concluded that close observation by well-trained personnel is needed, due to serious adverse effects from unintentional misuse or even in normal use.<xref rid="b26-jpr-7-449" ref-type="bibr">26</xref> In cases of severe bradypnea, naloxone can be used to treat the symptoms promptly.<xref rid="b27-jpr-7-449" ref-type="bibr">27</xref> Since the duration of TFPs is much longer than naloxone, one dose of naloxone may be insufficient, and a continuous infusion may be needed.</p><p>The TFP has many advantages: it can easily adhere to the skin, obviating an intravenous line, so there is little risk of infection, it is easily procured and costs less than a PCA pump, and it needs no programming, so no human error occurs.<xref rid="b14-jpr-7-449" ref-type="bibr">14</xref> It may be a good alternative in acute pain management.</p><sec sec-type="methods"><title>Limitations of the study</title><p>Despite our using safer TFP dosing (50 &#x003bc;g/hour), the sample size of the study was limited, so we cannot conclude that there is no danger of severe respiratory depression. As our inclusion criteria included an ASA physical status of I&#x02013;II and since these patients very often had an ASA physical status of III, we cannot conclude whether the TFP is suitable for use in these patients. Similarly, we cannot conclude whether or not TFPs would be effective for other major surgeries either. Further studies with larger sample sizes are needed to address these issues.</p></sec></sec><sec><title>Conclusion</title><p>A TFP (50 &#x003bc;g/hour) applied 10&#x02013;12 hours before surgery can be used as a postoperative analgesic for TKA, and can reduce morphine consumption over 48 hours by more than 55% without serious complications. The patients were more comfortable, and this was evidenced by lower pain scores both at rest and during movement. TFPs, we propose, may be effectively used in multimodal mode, in conjunction with other moderate analgesics (eg, NSAIDs) in accordance with the World Health Organization pain ladder.<xref rid="b28-jpr-7-449" ref-type="bibr">28</xref> Severe bradypnea may however occur as a result of any route of narcotic administration, so close monitoring by well-trained personnel &#x02013; having naloxone close at hand in the event of severe respiratory depression &#x02013; is recommended.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by the Faculty of Medicine, Khon Kaen University. We thank the patients and their families for their participation, the hospital pharmacy staff for their assistance, the nursing staff for their coordination, and Mr Bryan Roderick Hamman and Mrs Janice Loewen-Hamman for assistance with the English language presentation of the manuscript.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-jpr-7-449"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>JG</given-names></name><name><surname>Denny</surname><given-names>NM</given-names></name><name><surname>Oakman</surname><given-names>N</given-names></name></person-group><article-title>Postoperative analgesia following total knee arthroplasty: a study comparing spinal anesthesia and combined sciatic femoral 3-in-1 block</article-title><source>Reg Anesth Pain Med</source><year>1998</year><volume>23</volume><issue>2</issue><fpage>142</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">9570601</pub-id></element-citation></ref><ref id="b2-jpr-7-449"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>PT</given-names></name><name><surname>Bhandari</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>J</given-names></name><name><surname>Douketis</surname><given-names>J</given-names></name></person-group><article-title>Epidural analgesia for pain relief following hip or knee replacement</article-title><source>Cochrane Database Syst Rev</source><year>2003</year><issue>3</issue><fpage>CD003071</fpage><pub-id pub-id-type="pmid">12917945</pub-id></element-citation></ref><ref id="b3-jpr-7-449"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>JE</given-names></name><name><surname>Arya</surname><given-names>A</given-names></name><name><surname>Hurlburt</surname><given-names>L</given-names></name><etal/></person-group><article-title>Femoral nerve block improves analgesia outcomes after total knee arthroplasty: a meta-analysis of randomized controlled trials</article-title><source>Anesthesiology</source><year>2010</year><volume>113</volume><issue>5</issue><fpage>1144</fpage><lpage>1162</lpage><pub-id pub-id-type="pmid">20966667</pub-id></element-citation></ref><ref id="b4-jpr-7-449"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertini</surname><given-names>L</given-names></name><name><surname>Tagariello</surname><given-names>V</given-names></name><name><surname>Molino</surname><given-names>FM</given-names></name><name><surname>Posteraro</surname><given-names>CM</given-names></name><name><surname>Mancini</surname><given-names>S</given-names></name><name><surname>Rossignoli</surname><given-names>L</given-names></name></person-group><article-title>Patient-controlled postoperative analgesia in orthopedic surgery: epidural PCA versus intravenous PCA</article-title><source>Minerva Anestesiol</source><year>1995</year><volume>61</volume><issue>7&#x02013;8</issue><fpage>319</fpage><lpage>328</lpage><comment>Italian</comment><pub-id pub-id-type="pmid">8948744</pub-id></element-citation></ref><ref id="b5-jpr-7-449"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frassanito</surname><given-names>L</given-names></name><name><surname>Vergari</surname><given-names>A</given-names></name><name><surname>Zanghi</surname><given-names>F</given-names></name><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Bitondo</surname><given-names>M</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name></person-group><article-title>Post-operative analgesia following total knee arthroplasty: comparison of low-dose intrathecal morphine and single-shot ultrasound-guided femoral nerve block: a randomized, single blinded, controlled study</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2010</year><volume>14</volume><issue>7</issue><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">20707248</pub-id></element-citation></ref><ref id="b6-jpr-7-449"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaloul</surname><given-names>I</given-names></name><name><surname>Guay</surname><given-names>J</given-names></name><name><surname>C&#x000f4;t&#x000e9;</surname><given-names>C</given-names></name><name><surname>Fallaha</surname><given-names>M</given-names></name></person-group><article-title>The posterior lumbar plexus (psoas compartment) block and the three-in-one femoral nerve block provide similar postoperative analgesia after total knee replacement</article-title><source>Can J Anaesth</source><year>2004</year><volume>51</volume><issue>1</issue><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">14709460</pub-id></element-citation></ref><ref id="b7-jpr-7-449"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>JP</given-names></name><name><surname>Bower</surname><given-names>S</given-names></name><name><surname>Liddle</surname><given-names>AM</given-names></name><name><surname>Rowbotham</surname><given-names>DJ</given-names></name></person-group><article-title>Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients</article-title><source>Br J Anaesth</source><year>1998</year><volume>81</volume><issue>2</issue><fpage>152</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">9813514</pub-id></element-citation></ref><ref id="b8-jpr-7-449"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duthie</surname><given-names>DJ</given-names></name><name><surname>Rowbotham</surname><given-names>DJ</given-names></name><name><surname>Wyld</surname><given-names>R</given-names></name><name><surname>Henderson</surname><given-names>PD</given-names></name><name><surname>Nimmo</surname><given-names>WS</given-names></name></person-group><article-title>Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients</article-title><source>Br J Anaesth</source><year>1988</year><volume>60</volume><issue>6</issue><fpage>614</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">3377943</pub-id></element-citation></ref><ref id="b9-jpr-7-449"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornick</surname><given-names>CA</given-names></name><name><surname>Santiago-Palma</surname><given-names>J</given-names></name><name><surname>Khojainova</surname><given-names>N</given-names></name><name><surname>Primavera</surname><given-names>LH</given-names></name><name><surname>Payne</surname><given-names>R</given-names></name><name><surname>Manfredi</surname><given-names>PL</given-names></name></person-group><article-title>A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl</article-title><source>Cancer</source><year>2001</year><volume>92</volume><issue>12</issue><fpage>3056</fpage><lpage>3061</lpage><pub-id pub-id-type="pmid">11753984</pub-id></element-citation></ref><ref id="b10-jpr-7-449"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kornick</surname><given-names>CA</given-names></name><name><surname>Santiago-Palma</surname><given-names>J</given-names></name><name><surname>Moryl</surname><given-names>N</given-names></name><name><surname>Payne</surname><given-names>R</given-names></name><name><surname>Obbens</surname><given-names>EA</given-names></name></person-group><article-title>Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain</article-title><source>Drug Saf</source><year>2003</year><volume>26</volume><issue>13</issue><fpage>951</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">14583070</pub-id></element-citation></ref><ref id="b11-jpr-7-449"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holley</surname><given-names>FO</given-names></name><name><surname>van Steennis</surname><given-names>C</given-names></name></person-group><article-title>Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate iv and transdermal delivery</article-title><source>Br J Anaesth</source><year>1988</year><volume>60</volume><issue>6</issue><fpage>608</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">3377942</pub-id></element-citation></ref><ref id="b12-jpr-7-449"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Est&#x000e8;ve</surname><given-names>M</given-names></name></person-group><article-title>Transcutaneous fentanyl</article-title><source>Cah Anesthesiol</source><year>1994</year><volume>42</volume><issue>2</issue><fpage>195</fpage><lpage>217</lpage><comment>French</comment><pub-id pub-id-type="pmid">8087637</pub-id></element-citation></ref><ref id="b13-jpr-7-449"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grond</surname><given-names>S</given-names></name><name><surname>Radbruch</surname><given-names>L</given-names></name><name><surname>Lehmann</surname><given-names>KA</given-names></name></person-group><article-title>Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl</article-title><source>Clin Pharmacokinet</source><year>2000</year><volume>38</volume><issue>1</issue><fpage>59</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">10668859</pub-id></element-citation></ref><ref id="b14-jpr-7-449"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minville</surname><given-names>V</given-names></name><name><surname>Lubrano</surname><given-names>V</given-names></name><name><surname>Bounes</surname><given-names>V</given-names></name><etal/></person-group><article-title>Postoperative analgesia after total hip arthroplasty: patient-controlled analgesia versus transdermal fentanyl patch</article-title><source>J Clin Anesth</source><year>2008</year><volume>20</volume><issue>4</issue><fpage>280</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">18617126</pub-id></element-citation></ref><ref id="b15-jpr-7-449"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broome</surname><given-names>IJ</given-names></name><name><surname>Wright</surname><given-names>BM</given-names></name><name><surname>Bower</surname><given-names>S</given-names></name><name><surname>Reilly</surname><given-names>CS</given-names></name></person-group><article-title>Postoperative analgesia with transdermal fentanyl following lower abdominal surgery</article-title><source>Anaesthesia</source><year>1995</year><volume>50</volume><issue>4</issue><fpage>300</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">7747844</pub-id></element-citation></ref><ref id="b16-jpr-7-449"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caplan</surname><given-names>RA</given-names></name><name><surname>Ready</surname><given-names>LB</given-names></name><name><surname>Oden</surname><given-names>RV</given-names></name><name><surname>Matsen</surname><given-names>FA</given-names><suffix>3rd</suffix></name><name><surname>Nessly</surname><given-names>ML</given-names></name><name><surname>Olsson</surname><given-names>GL</given-names></name></person-group><article-title>Transdermal fentanyl for postoperative pain management. A double-blind placebo study</article-title><source>JAMA</source><year>1989</year><volume>261</volume><issue>7</issue><fpage>1036</fpage><lpage>1039</lpage><pub-id pub-id-type="pmid">2915410</pub-id></element-citation></ref><ref id="b17-jpr-7-449"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilbride</surname><given-names>M</given-names></name><name><surname>Morse</surname><given-names>M</given-names></name><name><surname>Senagore</surname><given-names>A</given-names></name></person-group><article-title>Transdermal fentanyl improves management of postoperative hemorrhoidectomy pain</article-title><source>Dis Colon Rectum</source><year>1994</year><volume>37</volume><issue>11</issue><fpage>1070</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">7956571</pub-id></element-citation></ref><ref id="b18-jpr-7-449"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>KA</given-names></name><name><surname>Einnolf</surname><given-names>C</given-names></name><name><surname>Eberlein</surname><given-names>HJ</given-names></name><name><surname>Nagel</surname><given-names>R</given-names></name></person-group><article-title>Transdermal fentanyl for the treatment of pain after major urological operations. A randomized double-blind comparison with placebo using intravenous patient-controlled analgesia</article-title><source>Eur J Clin Pharmacol</source><year>1991</year><volume>41</volume><issue>1</issue><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">1782972</pub-id></element-citation></ref><ref id="b19-jpr-7-449"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>LJ</given-names></name><name><surname>DeSio</surname><given-names>JM</given-names></name><name><surname>Radvany</surname><given-names>T</given-names></name><name><surname>Bikhazi</surname><given-names>GB</given-names></name></person-group><article-title>Transdermal fentanyl in postoperative pain</article-title><source>Reg Anesth</source><year>1997</year><volume>22</volume><issue>1</issue><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">9010943</pub-id></element-citation></ref><ref id="b20-jpr-7-449"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sevarino</surname><given-names>FB</given-names></name><name><surname>Naulty</surname><given-names>JS</given-names></name><name><surname>Sinatra</surname><given-names>R</given-names></name><etal/></person-group><article-title>Transdermal fentanyl for postoperative pain management in patients recovering from abdominal gynecologic surgery</article-title><source>Anesthesiology</source><year>1992</year><volume>77</volume><issue>3</issue><fpage>463</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">1519784</pub-id></element-citation></ref><ref id="b21-jpr-7-449"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowbotham</surname><given-names>DJ</given-names></name><name><surname>Wyld</surname><given-names>R</given-names></name><name><surname>Peacock</surname><given-names>JE</given-names></name><name><surname>Duthie</surname><given-names>DJ</given-names></name><name><surname>Nimmo</surname><given-names>WS</given-names></name></person-group><article-title>Transdermal fentanyl for the relief of pain after upper abdominal surgery</article-title><source>Br J Anaesth</source><year>1989</year><volume>63</volume><issue>1</issue><fpage>56</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">2669904</pub-id></element-citation></ref><ref id="b22-jpr-7-449"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osipova</surname><given-names>NA</given-names></name><name><surname>Petrova</surname><given-names>VV</given-names></name><name><surname>Lastukhin</surname><given-names>AV</given-names></name><name><surname>Kudriavtsev</surname><given-names>SB</given-names></name><name><surname>Vashakmadze</surname><given-names>LA</given-names></name><name><surname>Khomiakov</surname><given-names>VM</given-names></name></person-group><article-title>Prevention and treatment of postoperative pain syndrome in extensive thoracoabdominal oncological surgery</article-title><source>Anesteziol Reanimatol</source><year>2010</year><issue>3</issue><fpage>29</fpage><lpage>33</lpage><comment>Russian</comment><pub-id pub-id-type="pmid">20734844</pub-id></element-citation></ref><ref id="b23-jpr-7-449"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>AN</given-names></name><name><surname>Baxter</surname><given-names>AD</given-names></name><name><surname>Katz</surname><given-names>J</given-names></name><etal/></person-group><article-title>A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory, and pharmacokinetic effects</article-title><source>Anesthesiology</source><year>1994</year><volume>81</volume><issue>5</issue><fpage>1169</fpage><lpage>1180</lpage><pub-id pub-id-type="pmid">7978475</pub-id></element-citation></ref><ref id="b24-jpr-7-449"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulow</surname><given-names>HH</given-names></name><name><surname>Linnemann</surname><given-names>M</given-names></name><name><surname>Berg</surname><given-names>H</given-names></name><name><surname>Lang-Jensen</surname><given-names>T</given-names></name><name><surname>LaCour</surname><given-names>S</given-names></name><name><surname>Jonsson</surname><given-names>T</given-names></name></person-group><article-title>Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl</article-title><source>Acta Anaesthesiol Scand</source><year>1995</year><volume>39</volume><issue>6</issue><fpage>835</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">7484044</pub-id></element-citation></ref><ref id="b25-jpr-7-449"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>JM</given-names></name><name><surname>Best</surname><given-names>BM</given-names></name><name><surname>Pesce</surname><given-names>AJ</given-names></name></person-group><article-title>Variability of transdermal fentanyl metabolism and excretion in pain patients</article-title><source>J Opioid Manag</source><year>2010</year><volume>6</volume><issue>1</issue><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">20297612</pub-id></element-citation></ref><ref id="b26-jpr-7-449"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>L</given-names></name><name><surname>Schwaner</surname><given-names>R</given-names></name></person-group><article-title>Transdermal fentanyl: pharmacology and toxicology</article-title><source>J Med Toxicol</source><year>2009</year><volume>5</volume><issue>4</issue><fpage>230</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">19876859</pub-id></element-citation></ref><ref id="b27-jpr-7-449"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Bastelaere</surname><given-names>M</given-names></name><name><surname>Rolly</surname><given-names>G</given-names></name><name><surname>Abdullah</surname><given-names>NM</given-names></name></person-group><article-title>Postoperative analgesia and plasma levels after transdermal fentanyl for orthopedic surgery: double-blind comparison with placebo</article-title><source>J Clin Anesth</source><year>1995</year><volume>7</volume><issue>10</issue><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">7772354</pub-id></element-citation></ref><ref id="b28-jpr-7-449"><label>28</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><source>WHO&#x02019;s cancer pain ladder for adults</source><year>2009</year><comment>Avaialble from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/cancer/palliative/painladder/en">http://www.who.int/cancer/palliative/painladder/en</ext-link></comment><date-in-citation>Accessed July 2, 2014</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig id="f1-jpr-7-449" position="float"><label>Figure 1</label><caption><p>Flowchart for patient recruitment, randomization, and follow-up.</p><p><bold>Abbreviation:</bold> TFP, transdermal fentanyl patch.</p></caption><graphic xlink:href="jpr-7-449Fig1"/></fig><fig id="f2-jpr-7-449" position="float"><label>Figure 2</label><caption><p>Cumulative morphine consumption over 48 hours.</p><p><bold>Notes:</bold> *<italic>P</italic>&#x02264;0.001. Group T patients received a transdermal fentanyl patch; group P patients received placebo.</p><p><bold>Abbreviation:</bold> PACU, postanesthetic care unit.</p></caption><graphic xlink:href="jpr-7-449Fig2"/></fig><fig id="f3-jpr-7-449" position="float"><label>Figure 3</label><caption><p>Numeric rating pain score at rest and during movement over 48 hours.</p><p><bold>Notes:</bold> **<italic>P</italic>=0.002. Group T patients received a transdermal fentanyl patch; group P patients received placebo. Data presented as means (standard deviation).</p><p><bold>Abbreviation:</bold> NRS, numeric rating scale.</p></caption><graphic xlink:href="jpr-7-449Fig3"/></fig><table-wrap id="t1-jpr-7-449" position="float"><label>Table 1</label><caption><p>Demographic and operative data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Group T<break/>(n=20)</th><th align="left" valign="top" rowspan="1" colspan="1">Group P<break/>(n=20)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">64.90 (7.31)</td><td align="left" valign="top" rowspan="1" colspan="1">66.20 (8.48)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (85%)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (95%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASA physical status (I:II)</td><td align="left" valign="top" rowspan="1" colspan="1">20:0</td><td align="left" valign="top" rowspan="1" colspan="1">15:5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">66.65 (7.54)</td><td align="left" valign="top" rowspan="1" colspan="1">63.05 (9.46)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height (cm)</td><td align="left" valign="top" rowspan="1" colspan="1">155.35 (5.57)</td><td align="left" valign="top" rowspan="1" colspan="1">153.40 (5.45)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">27.64 (3.10)</td><td align="left" valign="top" rowspan="1" colspan="1">26.88 (4.45)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anesthetic time (minutes)</td><td align="left" valign="top" rowspan="1" colspan="1">168.50 (54.65)</td><td align="left" valign="top" rowspan="1" colspan="1">159.00 (40.31)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-jpr-7-449"><p><bold>Notes:</bold> Group T patients received a transdermal fentanyl patch; group P patients received placebo. Data for age, weight, height, BMI, and anesthetic time are presented as means (standard deviation).</p></fn><fn id="tfn2-jpr-7-449"><p><bold>Abbreviations:</bold> ASA, American Society of Anesthesiologists; BMI, body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-jpr-7-449" position="float"><label>Table 2</label><caption><p>Morphine consumption and NRS, ambulation, sedation, and N/V scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Group T (n=20)</th><th align="left" valign="top" rowspan="1" colspan="1">Group P (n=20)</th><th align="left" valign="top" rowspan="1" colspan="1">Mean difference</th><th align="left" valign="top" rowspan="1" colspan="1">95% CI</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Morphine consumption in 24 hours (mg)</td><td align="left" valign="top" rowspan="1" colspan="1">15.40 (12.65)</td><td align="left" valign="top" rowspan="1" colspan="1">33.60 (19.06)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;18.20</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;28.55 to &#x02212;7.85</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Morphine consumption in 48 hours (mg)</td><td align="left" valign="top" rowspan="1" colspan="1">24.90 (20.11)</td><td align="left" valign="top" rowspan="1" colspan="1">57.80 (28.70)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;32.90</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;48.76 to &#x02212;17.04</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NRS score at rest</td><td align="left" valign="top" rowspan="1" colspan="1">2.73 (1.95)</td><td align="left" valign="top" rowspan="1" colspan="1">4.64 (1.60)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.91</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.05 to &#x02212;0.77</td><td align="left" valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NRS score during movement</td><td align="left" valign="top" rowspan="1" colspan="1">4.39 (2.37)</td><td align="left" valign="top" rowspan="1" colspan="1">6.42 (1.40)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.02</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.27 to &#x02212;0.78</td><td align="left" valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ambulation score</td><td align="left" valign="top" rowspan="1" colspan="1">0.60 (0.18)</td><td align="left" valign="top" rowspan="1" colspan="1">0.44 (0.23)</td><td align="left" valign="top" rowspan="1" colspan="1">0.15</td><td align="left" valign="top" rowspan="1" colspan="1">0.02 to 0.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sedation score</td><td align="left" valign="top" rowspan="1" colspan="1">0.27 (0.29)</td><td align="left" valign="top" rowspan="1" colspan="1">0.18 (0.23)</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.08 to 0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.299</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">N/V score</td><td align="left" valign="top" rowspan="1" colspan="1">0.59 (0.44)</td><td align="left" valign="top" rowspan="1" colspan="1">0.31 (0.38)</td><td align="left" valign="top" rowspan="1" colspan="1">0.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.02 to 0.55</td><td align="left" valign="top" rowspan="1" colspan="1">0.033</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-jpr-7-449"><p><bold>Notes:</bold> Group T patients received a transdermal fentanyl patch; group P patients received placebo. Data presented as means (standard deviation).</p></fn><fn id="tfn4-jpr-7-449"><p><bold>Abbreviations:</bold> CI, confidence interval; NRS, numeric rating scale; N/V, nausea/vomiting.</p></fn></table-wrap-foot></table-wrap></floats-group></article>